DNB Carnegie analyst Erik Hultgard upgraded Camurus (CAMRF) to Buy from Hold with an SEK 800 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAMRF:
- Camurus’ Oczyesa Gains EU Approval for Acromegaly Treatment
- Camurus Expands Share Count to Support Employee Incentive Program
- Camurus’ POSITANO Study Shows Promising Results for PLD Treatment
- Camurus, Lilly enter collaboration pact for long-acting FluidCrystal incretins
- Camurus Partners with Eli Lilly for Long-Acting Incretin Therapies